Market Overview

Wedbush Maintains Outperform on Sarepta Therapeutics, Inc., Lowers PT to $60.00

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for SRPT

DateFirmActionFromTo
May 2015Bank of AmericaDowngradesBuyNeutral
May 2015SunTrust Robinson HumphreyUpgradesNeutralBuy
May 2015Canaccord GenuityUpgradesHoldBuy

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: News Price Target Analyst Ratings

 

Related Articles (SRPT)

Get Benzinga's Newsletters